Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000592817 | SCV000705168 | uncertain significance | not provided | 2018-08-14 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001058506 | SCV001223083 | uncertain significance | Nephronophthisis | 2022-10-25 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 1004 of the NPHP4 protein (p.Thr1004Met). This variant is present in population databases (rs528511138, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with NPHP4-related conditions. ClinVar contains an entry for this variant (Variation ID: 499590). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt NPHP4 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002476307 | SCV002800935 | uncertain significance | Nephronophthisis 4; Senior-Loken syndrome 4 | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003278928 | SCV004008518 | uncertain significance | Inborn genetic diseases | 2023-05-05 | criteria provided, single submitter | clinical testing | The c.3011C>T (p.T1004M) alteration is located in exon 21 (coding exon 20) of the NPHP4 gene. This alteration results from a C to T substitution at nucleotide position 3011, causing the threonine (T) at amino acid position 1004 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Laboratory of Diagnostic Genome Analysis, |
RCV000592817 | SCV001798802 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000592817 | SCV001970738 | uncertain significance | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV004732958 | SCV005346037 | uncertain significance | NPHP4-related disorder | 2024-03-14 | no assertion criteria provided | clinical testing | The NPHP4 c.3011C>T variant is predicted to result in the amino acid substitution p.Thr1004Met. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.017% of alleles in individuals of European (Non-Finnish) descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |